Widespread extramedullary involvement in plasmablastic plasma cell myeloma: diagnostic challenges
38th European Congress of Pathology, Stockholm, İsveç, 12 - 16 Eylül 2026, cilt.489, sa.1, ss.731, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Cilt numarası: 489
- Doi Numarası: 10.1007/s00428-026-04642-8
- Basıldığı Şehir: Stockholm
- Basıldığı Ülke: İsveç
- Sayfa Sayıları: ss.731
- Manisa Celal Bayar Üniversitesi Adresli: Evet
Özet
Background & Objectives: Plasmablastic plasma cell myeloma (PB-PC myeloma) represents a rare and aggressive subtype of multiple myeloma, characterized by the presence of plasmablastic morphology and a elevated proliferative index. Its significant morphologic and immunophenotypic overlap with plasmablastic lymphoma poses a major diagnostic challenge, directly impacting therapeutic decision-making. Therefore, an integrated evaluation of clinical, radiological and pathological findings is essential for accurate diagnosis. Methods: A 55-year-old female patient was evaluated for hypercalcemia and found to have widespread multisystem involvement. PET-CT demonstrated multiple lesions in both breasts, mediastinal lymphadenopathy and diffuse hypermetabolic foci in liver, pancreas, stomach, perirenal regions, skeletal muscle and subcutaneous tissues. Tru-cut biopsies from iliac bone, breast and a bone marrow biopsy were performed and examined histologically, immunohistochemically and in-situ hybridization. Results: İliac bone biopsy revealed a neoplasm with plasmablastic morphology. Immunohistochemical analysis showed positivity for CD38, CD138, CD56 with negativity for CD19 and demonstrated monoclonal kappa light chain restriction. The Ki-67 proliferation index was 100%. Bone marrow biopsy revealed 95% cellularity with ~90% infiltration by blastic plasma cells. Breast biopsy showed a tumour with similar features. Considering the EBER-ISH negativity, presence of diffuse lytic bone lesions and immunophenotypic profile, a diagnosis of PB-PC myeloma were given. During clinical follow-up, the patient developed cranial involvement. During the intensive care unit the patient developed multi-organ failure and died shortly thereafter. Conclusion: PB-PC myeloma is associated with poor prognosis due to its high proliferative activity, extensive extramedullary involvement and rapid progression. In the differential diagnosis with plasmablastic lymphoma, key distinguishing features include EBER status, extent of bone marrow involvement, monoclonal light chain expression and clinical presentation. Additionally, a high Ki-67 index is an important indicator of aggressive clinical behaviour. This case highlights the extensive extramedullary dissemination potential and aggressive clinical course of plasmablastic myeloma. Accurate diagnosis requires a multidisciplinary approach and comprehensive immunophenotypic evaluation.